Fingerlakes Wealth Management Inc. Cuts Stock Position in Eli Lilly and Company $LLY

Fingerlakes Wealth Management Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,102 shares of the company’s stock after selling 17 shares during the quarter. Fingerlakes Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $859,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $35,000. Advantage Trust Co raised its stake in shares of Eli Lilly and Company by 27.0% during the second quarter. Advantage Trust Co now owns 876 shares of the company’s stock worth $683,000 after purchasing an additional 186 shares during the last quarter. DecisionMap Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 111.4% during the second quarter. DecisionMap Wealth Management LLC now owns 1,264 shares of the company’s stock worth $985,000 after purchasing an additional 666 shares during the last quarter. Divergent Planning LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $1,548,000. Finally, Syntegra Private Wealth Group LLC raised its stake in shares of Eli Lilly and Company by 27.0% during the second quarter. Syntegra Private Wealth Group LLC now owns 1,311 shares of the company’s stock worth $1,022,000 after purchasing an additional 279 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.8%

Eli Lilly and Company stock opened at $808.88 on Tuesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $765.57 billion, a price-to-earnings ratio of 52.87, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The stock’s fifty day moving average is $756.56 and its two-hundred day moving average is $766.20.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LLY shares. Morgan Stanley cut their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. BMO Capital Markets upped their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday. Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday, October 9th. UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Insider Buying and Selling

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.